U.S. Secondary Hyperoxaluria Drug Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

U.S. Secondary Hyperoxaluria Drug Market Overview

As per Data Bridge Market Research analysis The U.S. secondary hyperoxaluria drug market was valued at USD 2.40 billion in 2025 and is projected to reach USD 4.85 billion by 2033, growing at a CAGR of 9.2% from 2026 to 2033. The market is experiencing steady growth driven by increasing awareness of rare kidney disorders, advancements in targeted therapeutic approaches, and a growing emphasis on early diagnosis and disease management.

The rising prevalence of conditions associated with secondary hyperoxaluria, including gastrointestinal disorders, bariatric surgeries, and chronic kidney diseases, is contributing to greater demand for effective treatment options. In addition, ongoing research activities, expanding access to specialized nephrology care, and supportive regulatory initiatives for rare disease therapies are encouraging pharmaceutical companies to develop innovative drug candidates. The adoption of precision medicine strategies and improved screening programs is further supporting market expansion across hospitals, specialty clinics, and renal care centers in the United States.

Key Market Trends & Insights

• The Supplements segment led the market with a 46.8% share in 2025, driven by their widespread use as supportive therapy for reducing oxalate absorption, preventing kidney stone recurrence, and improving overall metabolic management.
• Reloxaliase are the fastest-growing type, projected to register a CAGR of 8.9%, reflecting the surge in interest in targeted therapies that directly reduce intestinal oxalate absorption.
• The Prescription segment dominated the drug type category with a 71.4% revenue share in 2025, led by the specialized nature of secondary hyperoxaluria treatment and the requirement for physician-guided disease management.
• Adults accounted for 82.6% of the market, preferred by the higher prevalence of secondary hyperoxaluria-associated conditions such as inflammatory bowel disease, bariatric surgery complications, and chronic kidney disorders among adult populations
• The Children segment is the fastest-growing population type category, with a CAGR of 7.9%, driven by improving diagnostic capabilities and increasing recognition of pediatric metabolic and gastrointestinal disorders linked to oxalate imbalance

Market Size & Forecast

• Global Market Value (2025): USD 2.40 Billion
• Expected Market Value (2033): USD 4.85 Billion
• Forecast CAGR (2026–2033): 9.2%

Report Scope and U.S. Secondary Hyperoxaluria Drug Market Segmentation

U.S. Secondary Hyperoxaluria Drug Market Trends

Trend: Growing Focus on Precision Medicine and RNA-Based Therapeutics

Healthcare providers and pharmaceutical companies are increasingly focusing on precision medicine approaches to improve outcomes for patients with secondary hyperoxaluria. Advances in RNA-based therapies, metabolic pathway modulation, and biomarker-driven treatment strategies are enabling more targeted disease management while reducing complications associated with recurrent kidney stone formation and progressive renal impairment. Academic research centers and rare disease networks are similarly supporting patient identification initiatives through advanced diagnostic technologies, while ongoing clinical studies continue to expand understanding of disease mechanisms and treatment effectiveness.

For instance, in March 2024, researchers across multiple U.S. nephrology institutions expanded investigations into RNA interference and oxalate-lowering therapeutic approaches, highlighting growing interest in precision treatment strategies for hyperoxaluria-related disorders.

U.S. Secondary Hyperoxaluria Drug Market Dynamics

Key Market Driver: Increasing Prevalence of Kidney Disorders and Rare Disease Awareness

The rising prevalence of chronic kidney diseases, gastrointestinal disorders, and conditions associated with elevated oxalate production has created substantial demand for effective secondary hyperoxaluria treatments. Healthcare providers, specialty nephrology centers, and patient advocacy organizations are emphasizing early diagnosis and intervention, improving treatment accessibility and patient outcomes. Expanding awareness programs and advancements in diagnostic capabilities are further supporting market growth by identifying previously undiagnosed or misdiagnosed cases across the United States.

For instance, in January 2024, several U.S. rare disease advocacy initiatives expanded educational campaigns focused on hyperoxaluria and kidney stone prevention, contributing to increased screening and disease recognition among at-risk populations.

Key Restraint/Challenge: Limited Patient Population and High Treatment Costs

A significant restraint in the U.S. secondary hyperoxaluria drug market is the relatively small patient population combined with the high cost of specialized therapies. Advanced treatments often require extensive research investment, complex manufacturing processes, and long development timelines, resulting in premium pricing and reimbursement challenges. The overall treatment burden may also include long-term monitoring, specialist consultations, and supportive renal care services, creating financial pressures for healthcare systems and patients despite clinical benefits.

For instance, in 2024, ongoing discussions among healthcare payers and rare disease treatment providers highlighted concerns regarding reimbursement and affordability of advanced metabolic disorder therapies, reflecting broader access challenges within the market.

Key Market Opportunity: Expansion of Rare Disease Drug Development Programs

The expansion of rare disease research and orphan drug development presents a significant market opportunity. Pharmaceutical companies are increasingly investing in novel oxalate-lowering therapies, targeted metabolic treatments, and next-generation biologics designed to address unmet clinical needs. Supportive regulatory pathways, orphan drug incentives, and growing collaboration between biotechnology firms and academic institutions are further accelerating innovation, creating opportunities for improved patient outcomes and broader treatment availability across the United States.

For instance, in June 2024, multiple biotechnology companies advanced clinical development programs targeting oxalate metabolism and kidney stone prevention, demonstrating the growing commercial and therapeutic potential of the secondary hyperoxaluria treatment landscape.

U.S. Secondary Hyperoxaluria Drug Market Scope

The U.S. secondary hyperoxaluria drug market is segmented on the basis of type, drug type, population type, end-users, and distribution channel.

• By Type

On the basis of type, the U.S. secondary hyperoxaluria drug market is segmented into Reloxaliase, Thiazide Diuretics, and Supplements. The Supplements segment dominated the market with an estimated 46.8% share in 2025, owing to their widespread use as supportive therapy for reducing oxalate absorption, preventing kidney stone recurrence, and improving overall metabolic management. Supplements such as calcium-based formulations and citrate products are commonly prescribed alongside dietary modifications, making them a standard component of long-term treatment plans. Their broad availability, favorable safety profile, and relatively lower cost compared to novel therapies support strong adoption. Physicians frequently recommend supplements as first-line management options for patients with mild-to-moderate disease manifestations. Growing awareness regarding preventive kidney health is further strengthening demand. Their established clinical utility continues to maintain segment leadership across the United States.

The Reloxaliase segment is projected to register the fastest growth at a CAGR of 8.9% from 2026 to 2033, driven by increasing interest in targeted therapies that directly reduce intestinal oxalate absorption. Reloxaliase offers a disease-focused mechanism designed to lower systemic oxalate burden and reduce the risk of kidney-related complications. Rising investment in rare disease drug development is supporting continued clinical evaluation and commercialization efforts. Healthcare providers are increasingly seeking alternatives to conventional symptom management approaches. Advances in precision medicine and growing demand for innovative therapies are further accelerating adoption. Expanding research activity and favorable regulatory support are expected to strengthen growth prospects during the forecast period.

• By Drug Type

On the basis of drug type, the U.S. secondary hyperoxaluria drug market is segmented into prescription and over the counter. The Prescription segment dominated the market with a 71.4% share in 2025, driven by the specialized nature of secondary hyperoxaluria treatment and the requirement for physician-guided disease management. Most advanced therapeutic options, including targeted metabolic treatments and disease-modifying drugs, are available only through prescription channels. Patients often require regular monitoring and dose adjustments under nephrology supervision, supporting strong demand for prescription medications. The segment also benefits from increasing diagnosis rates and referrals to specialty care centers. Reimbursement support for approved therapies further contributes to market leadership. Continuous innovation in rare disease therapeutics is expected to sustain demand within this segment.

The Over the Counter segment is expected to witness the fastest growth at a CAGR of 7.5% from 2026 to 2033, supported by increasing use of dietary supplements, citrate products, and preventive kidney health formulations. Consumers are becoming more proactive in managing kidney stone risk factors and maintaining urinary health. Greater awareness of oxalate-related disorders is encouraging self-care and preventive treatment approaches. Retail and online availability of supportive products is improving accessibility for patients. Growing interest in nutritional management strategies is further expanding adoption. The convenience and affordability associated with over-the-counter products are expected to drive steady growth throughout the forecast period.

• By Population Type

On the basis of population type, the U.S. secondary hyperoxaluria drug market is segmented into children and adults. The Adults segment accounted for the largest market share of 82.6% in 2025, owing to the higher prevalence of secondary hyperoxaluria-associated conditions such as inflammatory bowel disease, bariatric surgery complications, and chronic kidney disorders among adult populations. Adults are more likely to experience long-term dietary and metabolic factors that contribute to excessive oxalate accumulation. Increased healthcare utilization and access to specialized nephrology services also support diagnosis and treatment rates. The segment benefits from a larger patient pool requiring ongoing disease management. Growing awareness regarding kidney stone prevention is further strengthening demand. These factors collectively contribute to the segment’s dominant position.

The Children segment is projected to grow at the fastest pace with a CAGR of 7.9% from 2026 to 2033, driven by improving diagnostic capabilities and increasing recognition of pediatric metabolic and gastrointestinal disorders linked to oxalate imbalance. Healthcare providers are emphasizing earlier intervention to prevent long-term renal complications. Advances in pediatric nephrology and rare disease management are improving treatment accessibility. Growing awareness among caregivers and clinicians is contributing to higher screening rates. Research into age-appropriate therapies is also supporting market development. Enhanced monitoring programs and specialist care availability are expected to accelerate growth in this segment.

• By End-Users

On the basis of end-users, the U.S. secondary hyperoxaluria drug market is segmented into hospitals, homecare, specialty clinics, and others. The Hospitals segment dominated the market with a 44.9% share in 2025, driven by their role as primary centers for diagnosis, treatment initiation, and management of complex secondary hyperoxaluria cases. Hospitals provide access to multidisciplinary care teams, advanced diagnostic technologies, and specialized nephrology expertise. Patients with severe kidney complications often require hospital-based evaluation and treatment planning. The segment benefits from strong reimbursement support and integrated care pathways. Availability of prescription therapies and monitoring services further supports utilization. These factors continue to position hospitals as the leading end-user category.

The Specialty Clinics segment is expected to register the fastest growth at a CAGR of 8.2% from 2026 to 2033, supported by rising demand for focused nephrology and metabolic disorder management services. Specialty clinics offer personalized treatment plans, continuous patient monitoring, and improved access to rare disease expertise. Increasing referrals from primary care providers are contributing to patient volume growth. The expansion of outpatient care models is also supporting adoption. Patients often prefer specialty clinics due to shorter waiting times and disease-specific care. Growing investment in specialized renal care infrastructure is expected to further strengthen segment growth.

• By Distribution Channel

On the basis of distribution channel, the U.S. secondary hyperoxaluria drug market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The Hospital Pharmacy segment led the market with a 51.7% share in 2025, owing to the high utilization of prescription-based therapies that require specialist oversight and coordinated treatment management. Hospital pharmacies ensure proper dispensing, monitoring, and patient counseling for complex therapeutic regimens. They play a critical role in supporting patients receiving advanced or newly approved treatments. Strong integration with nephrology departments enhances treatment continuity and adherence. The segment also benefits from institutional purchasing agreements and reimbursement support. These advantages contribute to its dominant market position.

The Online Pharmacy segment is anticipated to witness the fastest growth at a CAGR of 8.6% from 2026 to 2033, driven by increasing digital healthcare adoption and growing consumer preference for convenient medication access. Online platforms provide home delivery services, improved price transparency, and easier refill management for long-term therapies. Expansion of telehealth services is further supporting online prescription fulfillment. Patients with chronic kidney conditions increasingly value the convenience offered by digital pharmacy channels. Technological advancements and secure e-commerce infrastructure are enhancing user confidence. As a result, online pharmacies are expected to experience robust growth throughout the forecast period.

U.S. Secondary Hyperoxaluria Drug Market Share

The U.S. secondary hyperoxaluria drug industry is primarily led by well-established companies, including:

• Alnylam Pharmaceuticals, Inc. (U.S.)
• Novo Nordisk A/S (Denmark)
• Arbor Biotechnologies, Inc. (U.S.)
• Synlogic Operating Company, Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Amgen Inc. (U.S.)
• OxThera AB (Sweden)
• Novartis AG (Switzerland)
• Hoffmann-La Roche Ltd (Switzerland)
• Sanofi (France)
• AstraZeneca (U.K.)
• Bayer AG (Germany)
• Takeda Pharmaceutical Company Limited (Japan)
• Vertex Pharmaceuticals Incorporated (U.S.)
• Travere Therapeutics, Inc. (U.S.)
• Ultragenyx Pharmaceutical Inc. (U.S.)
• Regeneron Pharmaceuticals, Inc. (U.S.)

Latest Developments in U.S. Secondary Hyperoxaluria Drug Market

• In April 2025, the FDA updated the U.S. prescribing information for OXLUMO (lumasiran), maintaining its indication for lowering urinary and plasma oxalate levels in pediatric and adult patients with Primary Hyperoxaluria Type 1 while incorporating updated post-marketing safety information and prescribing guidance. The revised label reflects continued regulatory oversight and supports confidence in long-term clinical use of RNAi-based therapies
• In March 2025, the U.S. Food and Drug Administration (FDA) approved Rivfloza (nedosiran) for children aged 2 years and older and adults with Primary Hyperoxaluria Type 1 (PH1) with relatively preserved kidney function. The approval expanded treatment availability to younger pediatric patients and reinforced the growing adoption of RNA interference (RNAi) therapies for oxalate-lowering treatment in the U.S. rare kidney disease landscape. This milestone further strengthened innovation in hyperoxaluria therapeutics and broadened treatment options for specialist nephrology centers
• In December 2024, Arbor Biotechnologies announced that the FDA accepted its Investigational New Drug (IND) application for ABO-101, a gene-editing therapy targeting Primary Hyperoxaluria Type 1, enabling initiation of the Phase 1/2 redePHine clinical trial in the United States. The program represents one of the first in vivo gene-editing approaches for hyperoxaluria and reflects continued investment in next-generation genetic therapies for oxalate-related diseases
• In October 2022, Alnylam Pharmaceuticals announced that the FDA approved a supplemental New Drug Application (sNDA) for OXLUMO (lumasiran), expanding its indication to include patients with severe renal impairment, including those receiving hemodialysis. The approval was supported by positive Phase 3 ILLUMINATE-C study results and significantly broadened the eligible patient population for this RNAi therapy in the United States
• In January 2022, Allena Pharmaceuticals announced plans to engage with the FDA regarding modifications to the pivotal URIROX-2 Phase 3 trial evaluating reloxaliase for enteric hyperoxaluria, with the objective of optimizing trial size and duration. The update highlighted the company's continued commitment to advancing a targeted oral enzyme therapy for patients with secondary (enteric) hyperoxaluria and addressing unmet treatment needs in the U.S. market

SKU-59988